Alkermes plc or PTC Therapeutics, Inc.: Who Manages SG&A Costs Better?

Alkermes vs. PTC: A Decade of SG&A Cost Management

__timestamp	Alkermes plc	PTC Therapeutics, Inc.
Wednesday, January 1, 2014	199905000	44820000
Thursday, January 1, 2015	311558000	82080000
Friday, January 1, 2016	374130000	97130000
Sunday, January 1, 2017	421578000	121271000
Monday, January 1, 2018	526408000	153548000
Tuesday, January 1, 2019	599449000	202541000
Wednesday, January 1, 2020	538827000	245164000
Friday, January 1, 2021	560977000	285773000
Saturday, January 1, 2022	605747000	325998000
Sunday, January 1, 2023	689751000	332540000
Monday, January 1, 2024	645238000

Unveiling the hidden dimensions of data

Managing SG&A Costs: Alkermes plc vs. PTC Therapeutics, Inc.

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Alkermes plc and PTC Therapeutics, Inc. have shown distinct approaches to handling these costs. From 2014 to 2023, Alkermes consistently reported higher SG&A expenses, peaking at approximately $690 million in 2023, a 245% increase from 2014. In contrast, PTC Therapeutics, Inc. demonstrated a more conservative growth in SG&A expenses, rising from $45 million in 2014 to $333 million in 2023, marking a 640% increase. This data suggests that while Alkermes operates on a larger scale, PTC Therapeutics is rapidly expanding its operational footprint. Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025